News
Public · Published
Shardul Amarchand Mangaldas & Co Advises Morgan Stanley PE On Its Stake Sale In Sahajanand Medical Technologies through IPO And Secondary Transfer
Shardul Amarchand Mangaldas & Co advised Morgan Stanley PE on selling 2,500,000 equity shares, about 2.46% of Sahajanand Medical Technologies, including Rs 45.93 crore through an offer for sale in its Rs 475.48 crore initial public offering and a Rs 40.06 crore secondary transfer.
Published:
Updated:
What happened
Shardul Amarchand Mangaldas & Co advised Morgan Stanley PE on selling 2,500,000 equity shares, about 2.46% of Sahajanand Medical Technologies, including Rs 45.93 crore through an offer for sale in its Rs 475.48 crore initial public offering and a Rs 40.06 crore secondary transfer.
Confirmed
Global impact / market context
The sale shifts a large block of Sahajanand Medical Technologies shares from a private equity owner to public investors, which can change who controls voting power and how freely the stock trades after listing on BSE and NSE.
Analyst inference
The deal shows private equity investors using Indian initial public offerings to exit medical device holdings. Sahajanand's presence in 65 countries makes it one of few listed medical device companies, giving public investors a rare way to own that sector.
Analyst inference
What to watch
- Morgan Stanley PE sold 1,335,178 shares worth Rs 45.93 crore through the offer for sale and 1,164,822 shares worth Rs 40.06 crore in a secondary transfer before the Rs 475.48 crore offer. Confirmed
- Track whether the book running lead managers, Motilal Oswal, Avendus, HSBC and Nuvama, keep the shares trading steadily after listing, since a weak aftermarket could discourage similar private equity exits. Proposed
- Watch Sahajanand's future disclosures for how the public shareholding and reduced private equity stake affect voting control and the company's ability to raise more capital for medical device expansion. Analyst inference
Evidence
- Original source link unavailable